
Positive results in Entera Bio’s pharmacokinetic (PK) & pharmacodynamic (PD) study in patients with hypoparathyroidism
Entera Bio Ltd. (Nasdaq: ENTX) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in

The New Scientist Reports on Biondvax’s Universal Flu Vaccine
For decades, scientists have been trying to develop a universal vaccine that would protect people against seasonal flu for years, and also against pandemics, which

Anchiano Therapeutics files for $30-40m Nasdaq offering
Jerusalem based cancer treatment company Anchiano Therapeutics (TASE: ANCN), formerly BioCancell Therapeutics, has announced the publication of a confidential prospectus for an offering on Nasdaq. It is

Results of Zion Medical’s First Human Clinical Trial of HIV drug Gammora Offers Potential Cure
Zion Medical, an Israeli biotech company developing HIV and cancer treatments, has announced the results of the first clinical trial of HIV-drug Gammora, eliminating up

Hebrew U Researchers Develop Technology for 3-D Printing of Drugs
Researchers from Jerusalem’s Hebrew University unveiled their novel technology for three-dimensional printing of drug capsules on Wednesday, enabling the customization and personalization of medications unavailable

JLM-based Gamida Cell to raise $69m in Nasdaq IPO/adds Robert Blum as new Chairman of the Board
Jerusalem stem cell cancer therapy developer Gamida Cell Ltd. has filed a registration statement on Form F-1 with the US Securities and Exchange Commission (SEC)

CDC sponsored study: Argaman Technologies reduced by 25% hospital acquired infections and by 40% Multi-Drug Resistant Organisms in Wards!
The University of Pennsylvania Medical School Hospital is to announce the results of a study on the impact of Argaman Technologies in a hospital at the

Densys3D Announces US Dental Depot as Regional US Distributor
Densys3d has entered into a strategic agreement with US Dental Depot as a regional distributor for their intraoral scanner, MIA3D software, and speed scanner spray. This

Hadassah Hebrew U BioDesign Project, CardioVia, Raises NIS 3 Million & Was Accepted to the NGT3 VC Incubator
Following the June 2018 presentation of bio-med projects in the framework of the BioDesign, a joint program of Hadassah Medical Center and the Hebrew University